A5039777507- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Contact Dermatitis and Allergies
- Nail Diseases and Treatments
- Cutaneous lymphoproliferative disorders research
- Autoimmune and Inflammatory Disorders
- Psoriasis: Treatment and Pathogenesis
- Transgenic Plants and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Medicine and Dermatology Studies History
- Clinical practice guidelines implementation
- Neonatal skin health care
- Dermatological and Skeletal Disorders
- Delphi Technique in Research
- Dermatological and COVID-19 studies
- Pharmaceutical studies and practices
- Adrenal Hormones and Disorders
- Vascular Malformations and Hemangiomas
- Dermatologic Treatments and Research
- Cutaneous Melanoma Detection and Management
- Child Nutrition and Feeding Issues
Guy's and St Thomas' NHS Foundation Trust
2016-2025
King's College London
2016-2025
Guy's Hospital
2015-2025
Institute of Dermatology
2011-2025
St. John's School
2023-2024
St John's Hospital
2015-2024
Oxford University Hospitals NHS Trust
2023
St Thomas' Hospital
2014-2023
International League of Dermatological Societies
2023
National Health Service
2016-2021
The age at which allergenic foods should be introduced into the diet of breast-fed infants is uncertain. We evaluated whether early introduction in would protect against development food allergy.We recruited, from general population, 1303 exclusively who were 3 months and randomly assigned them to six (peanut, cooked egg, cow's milk, sesame, whitefish, wheat; early-introduction group) or current practice recommended United Kingdom exclusive breast-feeding approximately 6...
Disability secondary to skin conditions is substantial worldwide. The Global Burden of Disease Study 2013 includes estimates global morbidity and mortality due diseases.To measure the burden diseases worldwide.For nonfatal estimates, data were found by literature search using PubMed Google Scholar in English Spanish for years 1980 through accessing administrative on hospital inpatient outpatient episodes. Data fatal based vital registration verbal autopsy data.Skin disease extracted from...
The Global Burden of Disease (GBD) Study provides an annually updated resource to study disease‐related morbidity and mortality worldwide. Here we present the burden estimates for atopic dermatitis (AD), including data from inception GBD project in 1990 until 2017. Data on AD were obtained Study. Atopic (AD) ranks 15th among all nonfatal diseases has highest disease skin as measured by disability‐adjusted life‐years (DALYs). Overall, global DALY rate was 121 [95% uncertainty interval (UI)...
BackgroundInterleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator atopic dermatitis (AD).ObjectiveWe investigated the efficacy safety of lebrikizumab, IL-13 monoclonal antibody, as add-on to topical corticosteroid (TCS) treatment.MethodsA randomized, placebo-controlled, double-blind, phase study. Adults with moderate-to-severe AD were required use TCS twice daily then randomized (1:1:1:1) lebrikizumab 125 mg single dose, 250 every 4 weeks for 12...
BackgroundSkin barrier dysfunction precedes eczema development. We tested whether daily use of emollient in the first year could prevent high-risk children.MethodsWe did a multicentre, pragmatic, parallel-group, randomised controlled trial 12 hospitals and four primary care sites across UK. Families were approached via antenatal or postnatal services for recruitment term infants (at least 37 weeks' gestation) at high risk developing (ie, one first-degree relative with parent-reported eczema,...
Abstract The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline Consensus Statement Development Manual. Four consensus conferences were held between December 2020 July 2021. Twenty‐nine experts (including clinicians patient representatives) from 12 European countries participated. This first part of includes general information its scope purpose, health questions covered, target users a methods section. It also provides...
BackgroundThe influence of early exposure to allergenic foods on the subsequent development food allergy remains uncertain.ObjectiveWe sought determine feasibility introduction multiple exclusively breast-fed infants from 3 months age and effect breastfeeding performance.MethodsWe performed a randomized controlled trial. The group (EIG) continued with sequential 6 foods: cow's milk, peanut, hard-boiled hen's egg, sesame, whitefish (cod), wheat; standard followed UK infant feeding...
The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline Consensus Statement Development Manual. Four consensus conferences were held between December 2020 July 2021. Twenty-nine experts (including clinicians patient representatives) from 12 European countries participated. This second part of includes recommendations detailed information basic therapy emollients moisturizers, topical anti-inflammatory treatment, antimicrobial...
Dupilumab subcutaneous injection is approved for treating moderate-to-severe atopic dermatitis (AD) in adolescents, but there has been too little research on an efficacious systemic oral treatment with a favorable benefit-risk profile adolescents AD.To investigate the efficacy and safety of abrocitinib plus topical therapy AD.The phase 3, randomized, double-blind, placebo-controlled study JADE TEEN was conducted countries Asia-Pacific region, Europe, North America patients aged 12 to 17...
Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited.To evaluate the efficacy safety of interleukin-13-targeted treatment tralokinumab monotherapy in AD.The 52-week, randomized, double-blinded, placebo-controlled, phase 3 ECZTRA 6 trial was conducted from July 17, 2018, through March 16, 2021, at 72 centers across 10 countries North America, Europe, Asia, Australia. Enrolled patients were 12 17 years old AD (Investigator's Global...
Filaggrin loss-of-function (FLG) mutations are associated with eczema and skin barrier impairment, but it is unclear whether impairment precedes phenotypic in FLG mutation carriers.